Pharmacogenomics Market Report 2022: Increased Collaborations and Product Approvals to Drive Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Pharmacogenomics Market, by Technology, by Application, by End User, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
Pharmacogenomics is a branch of pharmacology that studies the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with drug efficacy or toxicity. It seeks to develop rational methods for optimizing drug therapy in relation to the patient’s genotype, in order to achieve maximum efficacy with minimal side effects.
Such approaches promise the advent of personalized medicine, in which drugs and drug combinations are optimized for each individual’s unique genetic makeup. Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs.
Market Dynamics
Key players operating in the global pharmacogenomics market are focusing on adoption of growth strategies such as collaborations and product approvals, which are expected to drive the market growth during the forecast period.
For instance, in February 2019, the University of Arizona College of Medicine-Phoenix and Banner Health collaborated to prevent life-threatening adverse reactions to medications. The Flinn Foundation is a privately endowed, philanthropic grant-making organization, awarded the Division of Clinical Data Analytics and Decision Support (CDADS) at the University of Arizona College of Medicine – Phoenix US$ 1.5 million to incorporate pharmacogenomics and clinical decision support into clinician training and medical practice.
Moreover, in December 2021, Thermo Fisher Scientific, a U.S-based supplier of scientific instrumentation, reagents and consumables, and software services, announced that U.S. FDA had granted premarket approval to Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT targeted therapy.
Key features of the study:
- This report provides in-depth analysis of the global pharmacogenomics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global pharmacogenomics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Admera Health, Abbott Laboratories, Agilent Technologies, Novartis AG, Dynamic DNA Laboratories, Empire Genomics, LLC., Hoffmann-La Roche Ltd., Illumina, Inc., OneOme, LLC, Myriad Genetics Inc., OPKO Health, Inc. (GeneDx.), Thermo Fisher Scientific, Inc., and AltheaDx
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global pharmacogenomics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pharmacogenomics market.
Detailed Segmentation:
Global Pharmacogenomics Market, By Technology :
- DNA Sequencing
- Microarray
- Polymerase Chain Reaction
- Electrophoresis
- Mass Spectrometry
- Other Technologies
Global Pharmacogenomics Market, By Application :
- Cardiovascular Diseases
- Infectious Diseases
- Oncology
- Neurological Diseases
- Psychiatry
- Pain Management
- Others
Global Pharmacogenomics Market, By End User :
- Hospitals & Clinics
- Research Institutions and Academic Institutes
- Others
Global Pharmacogenomics Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa/Sub-region
- South Africa
- Central Africa
- North Africa
Key Topics Covered:
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Pharmacogenomics Market – Impact of Coronavirus (COVID-19) Pandemic
5. Global Pharmacogenomics Market, By Technology, 2017-2030, (US$ Mn)
6. Global Pharmacogenomics Market, By Application, 2017-2030, (US$ Mn)
7. Global Pharmacogenomics Market, By End User, 2017-2030, (US$ Mn)
8. Global Pharmacogenomics Market, By Region, 2017-2030, (US$ Mn)
9. Competitive Landscape
10. Section
Companies Mentioned
- Admera Health.
- Abbott Laboratories
- Agilent Technologies
- Novartis AG
- Dynamic DNA Laboratories
- Empire Genomics, LLC
- F. Hoffmann-La Roche Ltd
- Illumina, Inc
- OneOme, LLC
- Myriad Genetics Inc
- OPKO Health, Inc. (GeneDx.)
- Thermo Fisher Scientific, Inc
- AltheaDx
For more information about this report visit https://www.researchandmarkets.com/r/q59cae
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
